Abstract
Antithrombotic treatment after heart valve surgery is of utmost importance depending on the type of used valve. Since in the early 1960s, oral anticoagulation with vitamin K antagonist are the gold-standard for prevention of thromboembolism at replaced heart valves. The introduction of new oral anticoagulation has dramatically changed treatment strategy in patients with atrial fibrillation and in patients with venous thromboembolism like deep vein thrombosis and pulmonary embolism. However, to date, the use of these newer drugs is contraindicated after implantation of mechanical heart valves for prevention of thromboembolism. Large trial revealed significantly higher rates of thromboembolism and bleeding events as compared to oral anticoagulation. Further studies are required to evaluate the several newer oral anticoagulations in patients with mechanical heart valve.
Keywords: Coumadin, heart valve, novel oral anticoagulation, surgery, warfarin.
Cardiovascular & Hematological Disorders-Drug Targets
Title:New Oral Anticoagulation after Heart Valve Replacement
Volume: 15 Issue: 2
Author(s): Ibrahim El-Battrawy, Stefan Baumann, Aydin Huseynov and Ibrahim Akin
Affiliation:
Keywords: Coumadin, heart valve, novel oral anticoagulation, surgery, warfarin.
Abstract: Antithrombotic treatment after heart valve surgery is of utmost importance depending on the type of used valve. Since in the early 1960s, oral anticoagulation with vitamin K antagonist are the gold-standard for prevention of thromboembolism at replaced heart valves. The introduction of new oral anticoagulation has dramatically changed treatment strategy in patients with atrial fibrillation and in patients with venous thromboembolism like deep vein thrombosis and pulmonary embolism. However, to date, the use of these newer drugs is contraindicated after implantation of mechanical heart valves for prevention of thromboembolism. Large trial revealed significantly higher rates of thromboembolism and bleeding events as compared to oral anticoagulation. Further studies are required to evaluate the several newer oral anticoagulations in patients with mechanical heart valve.
Export Options
About this article
Cite this article as:
El-Battrawy Ibrahim, Baumann Stefan, Huseynov Aydin and Akin Ibrahim, New Oral Anticoagulation after Heart Valve Replacement, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209111735
DOI https://dx.doi.org/10.2174/1871529X1502151209111735 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
Call for Papers in Thematic Issues
Effective Lowering pf Lipoprotein (a) – A new Frontier in Cardiovascular Risk Reduction
Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, causally linked to both atherosclerotic coronary artery disease and aortic valve stenosis. Elevated Lp(a) is widely prevalent, and several cardiovascular societies now recommend performing Lp(a) screening at least once in all adults. While, there are currently no approved drugs aimed ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Novel Insights into the Role of Anesthetics and Opioids in Organ or Tissue Protection)
Current Pharmaceutical Design Subject Index to Volume 1
Current Pharmacogenomics Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations
Current Medicinal Chemistry Viral Heart Disease and Acute Coronary Syndromes - Often or Rare Coexistence?
Current Pharmaceutical Design Involvement of the ADAM 12 in Thrombin-Induced Rat's VSMCs Proliferation
Current Medicinal Chemistry The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Identification and Quantitation of Some Characteristic Phenolic Compounds in Elderberry Juice by HPLC with Coulometric Electrode Array Detection
Current Bioactive Compounds Congenital Parenchymal Lesions of the Lung
Current Respiratory Medicine Reviews Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Cardiovascular Effects of Green Tea Catechins: Progress and Promise
Recent Patents on Cardiovascular Drug Discovery Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment
Current Pharmacogenomics and Personalized Medicine p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Chemistory of Fibrates
Current Chemical Biology Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies
Current Radiopharmaceuticals Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
Current Pharmaceutical Design